Freeline Therapeutics (FRLN) SC 13G/A Freeline Therapeutics / Syncona Portfolio ownership change

Exhibit 99.1

AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares (represented by ADS, each of which represents one Ordinary Share) of Freeline Therapeutics Holdings plc and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, as amended.

Dated:    February 11, 2022

SYNCONA PORTFOLIO LIMITED
By:	/s/ Rob Hutchinson
Name:	Rob Hutchinson
Title:	Director
SYNCONA HOLDINGS LIMITED
By:	/s/ Rob Hutchinson
Name:	Rob Hutchinson
Title:	Director
SYNCONA INVESTMENT MANAGEMENT LIMITED
By:	/s/ Martin Murphy
Name:	Martin Murphy
Title:	CEO
SYNCONA LIMITED
By:	/s/ Rob Hutchinson
Name:	Rob Hutchinson
Title:	Director
	/s/    Martin Murphy
	Martin Murphy
	/s/    Chris Hollowood
	Chris Hollowood